Avid Bioservices Inc (CDMO)

[cjgaddy]

Bidrite - “We expect the first results...Wolchok Lab...” - what we know (SITC Nov9-13)...

9-8-16/CC: JEFF HUTCHINS (VP/PreClinical Res.) http://tinyurl.com/jydtkoy
“. . .I would now like to provide an update on Peregrine's preclinical I-O focused internal efforts and our collaboration with Memorial Sloan Kettering Cancer Center. The goal of this work is to evaluate combinations of PS targeting with other checkpoint inhibitors and immune stimulatory agents for the purpose of developing new and increasingly effective anticancer treatments. These programs are advancing well and to-date, we have seen impressive signs of activity with new combinations of PS targeting and other treatment modalities such as checkpoint blockers, T-cell agonists and radiation. These new combinations are improving overall survival accompanied with increases in cyto-reactive T cells into the tumor tissue. This exciting new internal work will be presented at the AACR/CRI Immunotherapy Meeting in New York later this month [Sept25-28: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=101 ] and at ESMO in early October [Oct7-11: http://www.esmo.org/Conferences/ESMO-2016-Congress ].
We expect the first results from our collaboration with MSK’s JEDD WOLCHOK LAB investigators [See MSK Collab: http://tinyurl.com/zkvebh6 ] to be presented at SITC in November [Nov9-13: http://www.sitcancer.org/2016 ] and we will provide more detailed information as that presentation becomes available.”

Nov9-13: (SITC) Society for Immunotherapy of Cancer 31st Annual Meeting”, Natl-Harbor MD http://www.sitcancer.org/2016
...”First Results” from our collaboration with Jedd Wolchok Lab investigators (MSK) to be presented” (per 9-8-16/Ccall/Hutchins)